{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:41Z","timestamp":1792088201336,"version":"4.4.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Major Project of Science and Technology of Shandong Province","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}]},{"name":"The Natural Science-Crossing Disciplinary Cultivation Project of Shandong University","award":["2016JC032"],"award-info":[{"award-number":["2016JC032"]}]},{"name":"The Natural Science-Crossing Disciplinary Cultivation Project of Shandong University","award":["2017JC004"],"award-info":[{"award-number":["2017JC004"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.cbi.2018.09.019","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T11:11:26Z","timestamp":1538219486000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers"],"prefix":"10.1016","volume":"296","author":[{"given":"Yi-Fan","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ning","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Lian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2018.09.019_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopha.2016.06.047","article-title":"Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2\/M-phase arrest, independent of PPAR-\u03b3 pathway","volume":"83","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2018.09.019_bib2","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.3892\/or.2013.2704","article-title":"Effects of rosiglitazone on the growth and lymphangiogenesis of human gastric cancer transplanted in nude mice","volume":"30","author":"Chen","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2018.09.019_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/904041","article-title":"Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling","author":"Cantini","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1590\/1414-431x20144212","article-title":"PPARgamma induces growth inhibition and apoptosis through upregulation of insulin-like growth factor-binding protein-3 in gastric cancer cells","volume":"48","author":"Kim","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4067\/S0717-95022017000100042","article-title":"Rosiglitazone role in the expression of KLF6 Caco-2 colon cancer cells","volume":"35","author":"Rojas","year":"2017","journal-title":"Int. J. Morphol."},{"key":"10.1016\/j.cbi.2018.09.019_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/2050640616640443","article-title":"A PPAR-gamma agonist protects from radiation-induced intestinal toxicity","volume":"5","author":"Mangoni","year":"2017","journal-title":"United Eur Gastroent"},{"key":"10.1016\/j.cbi.2018.09.019_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.lungcan.2015.11.005","article-title":"A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model","volume":"90","author":"Mangoni","year":"2015","journal-title":"Lung Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.11.018","article-title":"A PPAR gamma agonist protects against oral mucositis induced by irradiation in a murine model","volume":"64","author":"Monica","year":"2017","journal-title":"Oral Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3892\/etm.2015.2934","article-title":"PPAR\u03b3 activation reduces ischemia\/reperfusion-induced metastasis in a murine model of hepatocellular carcinoma","volume":"11","author":"Liu","year":"2016","journal-title":"Experimental & Therapeutic Medicine"},{"key":"10.1016\/j.cbi.2018.09.019_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102758","article-title":"Oxaliplatin neurotoxicity involves peroxisome alterations. PPARgamma agonism as preventive pharmacological approach","volume":"9","author":"Zanardelli","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2018.09.019_bib11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bph.12202","article-title":"Increasing doxorubicin activity against breast cancer cells using PPARgamma-ligands and by exploiting circadian rhythms","volume":"169","author":"Arif","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2018.09.019_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/cbt.12.11.18134","article-title":"Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia","volume":"12","author":"Asp","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2018.09.019_bib13","first-page":"1","article-title":"Chemotherapy and chemoprevention by thiazolidinediones","volume":"2014","author":"Frohlich","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.cbi.2018.09.019_bib14","article-title":"PPAR\u03b3 mediated PTEN transcription via rosiglitazone stimulation","volume":"65","author":"Roof","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/aps.2009.119","article-title":"Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway","volume":"30","author":"Cao","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.cbi.2018.09.019_bib16","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1349-7006.2009.01389.x","article-title":"Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPAR gamma and inhibition of ERK 1\/2","volume":"101","author":"Moon","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cbi.2018.09.019_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1385\/MO:23:3:393","article-title":"Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375","volume":"23","author":"Li","year":"2006","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-9944-1","article-title":"Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells","volume":"113","author":"Bonofiglio","year":"2009","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.cbi.2018.09.019_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2008.10.023","article-title":"Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells","volume":"275","author":"Sun","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2018.09.019_bib20","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1158\/0008-5472.CAN-09-0219","article-title":"Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo","volume":"69","author":"Kumar","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib22","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/jcb.24580","article-title":"Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines","volume":"114","author":"Neeraja","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cbi.2018.09.019_bib23","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1038\/sj.onc.1206824","article-title":"Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line","volume":"22","author":"Pignatelli","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2018.09.019_bib24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1124\/mol.107.035584","article-title":"Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation","volume":"72","author":"Kim","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2018.09.019_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3892\/mmr.2014.2232","article-title":"Peroxisome proliferatoractivated receptor gamma agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4\/CXCL12 axis","volume":"10","author":"Qin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cbi.2018.09.019_bib26","doi-asserted-by":"crossref","first-page":"65109","DOI":"10.18632\/oncotarget.11371","article-title":"Ligand-activated PPAR\u03b3 downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression","volume":"7","author":"Rovito","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2018.09.019_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3892\/etm.2011.227","article-title":"Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line","volume":"2","author":"Miao","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.cbi.2018.09.019_bib28","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.biocel.2008.08.037","article-title":"PPARgamma agonists attenuate proliferation and modulate Wnt\/betacatenin signalling in melanoma cells","volume":"41","author":"Smith","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cbi.2018.09.019_bib29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","article-title":"Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes","volume":"26","author":"Zhang","year":"2015","journal-title":"Anti Canccer Drugs"},{"key":"10.1016\/j.cbi.2018.09.019_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2567.2009.03105.x","article-title":"Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma","volume":"128","author":"Zhao","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.cbi.2018.09.019_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-012-1324-3","article-title":"Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer","volume":"62","author":"Bunt","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cbi.2018.09.019_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1666","article-title":"Autophagy: dual roles in life and death?","volume":"6","author":"Baehrecke","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cbi.2018.09.019_bib33","article-title":"Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells","volume":"373","author":"Mellini","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.cbi.2018.09.019_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.yexcr.2011.02.014","article-title":"Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells","volume":"317","author":"Cerquetti","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10456-008-9118-0","article-title":"PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis","volume":"11","author":"Aljada","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cbi.2018.09.019_bib36","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3892\/mmr.2014.2407","article-title":"Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1alpha and insulin-like growth factor-1 mRNA expression","volume":"10","author":"Rui","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cbi.2018.09.019_bib37","doi-asserted-by":"crossref","first-page":"32234","DOI":"10.1074\/jbc.M001352200","article-title":"HCaRG, a novel calcium-regulated gene coding for a nuclear protein, is potentially involved in the regulation of cell proliferation","volume":"275","author":"Solban","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2018.09.019_bib38","first-page":"1093","article-title":"Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression","volume":"20","author":"Chen","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2018.09.019_bib39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1124\/mol.106.033357","article-title":"Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase","volume":"71","author":"Hazra","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2018.09.019_bib40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1096\/fj.03-0369fje","article-title":"COX-2-dependent stabilization of survivin in non-small cell lung cancer","volume":"18","author":"Krysan","year":"2004","journal-title":"Faseb. J."},{"key":"10.1016\/j.cbi.2018.09.019_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2018.09.019_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2407-10-95","article-title":"The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging","volume":"10","author":"Tai","year":"2010","journal-title":"BMC Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib43","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-07-5040","article-title":"Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor\u03b3 ligands in vitro and in vivo","volume":"14","author":"Hsu","year":"2008","journal-title":"Clinical Cancer Research An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/j.cbi.2018.09.019_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.freeradbiomed.2007.12.001","article-title":"Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP","volume":"44","author":"Kim","year":"2008","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.cbi.2018.09.019_bib45","first-page":"29632","article-title":"Rosiglitazone, an agonist of PPARgamma, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis Complex-2","volume":"2","author":"Han","year":"2007","journal-title":"PPAR Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.14735\/amko2015431","article-title":"Thiazolidinediones regulate the level of ABC transporters expression on lung cancer cells","volume":"28","author":"Konieczna","year":"2015","journal-title":"Klin. Onkol."},{"key":"10.1016\/j.cbi.2018.09.019_bib47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1535-7163.MCT-05-0347","article-title":"Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways","volume":"5","author":"Han","year":"2006","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2018.09.019_bib48","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1582-4934.2009.00966.x","article-title":"PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc\/Mad\/Max network in colon cancer cells","volume":"14","author":"Toaldo","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.cbi.2018.09.019_bib49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1443-9573.2007.00290.x","article-title":"Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer","volume":"8","author":"Lin","year":"2007","journal-title":"J Dig Dis"},{"key":"10.1016\/j.cbi.2018.09.019_bib50","first-page":"1215","article-title":"Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner","volume":"30","author":"Richard","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib51","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1210\/me.2006-0192","article-title":"Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells","volume":"20","author":"Bonofiglio","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cbi.2018.09.019_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2407-8-47","article-title":"Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3","volume":"8","author":"Magenta","year":"2008","journal-title":"BMC Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0006-291X(02)02983-2","article-title":"Activation of PPARgamma increases PTEN expression in pancreatic cancer cells","volume":"301","author":"Farrow","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2018.09.019_bib54","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3748\/wjg.15.441","article-title":"Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition","volume":"15","author":"Dong","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cbi.2018.09.019_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2015.01.004","article-title":"Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibits hepatoma cell growth via downregulation of SEPT2 expression","volume":"359","author":"Cao","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2018.09.019_bib56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.5.8.2887","article-title":"PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404","volume":"5","author":"Zhang","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2018.09.019_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12013-010-9136-6","article-title":"PPARgamma agonist suppresses TLR4 expression and TNF-alpha production in LPS stimulated monocyte leukemia cells","volume":"60","author":"Wang","year":"2011","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.cbi.2018.09.019_bib58","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.4161\/cc.20770","article-title":"Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells","volume":"11","author":"Pan","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cbi.2018.09.019_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1091581809335312","article-title":"Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone--induced apoptosis in leukemia k562 cells and its mechanisms of action","volume":"28","author":"Liu","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.cbi.2018.09.019_bib60","doi-asserted-by":"crossref","first-page":"352B","DOI":"10.1182\/blood.V108.11.5052.5052","article-title":"Ex vivo anti-tumor activity of rosiglitazone on multiple myeloma cells","volume":"108","author":"Huang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2018.09.019_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/ERC-09-0170","article-title":"Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model","volume":"17","author":"Luconi","year":"2010","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.cbi.2018.09.019_bib62","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.yexcr.2011.02.014","article-title":"Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells","volume":"317","author":"Cerquetti","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib63","series-title":"Vitro Cell Dev-An. 42S","article-title":"Response of rosiglitazone, UAB 30, and atorvastatin in the human melanoma prevention assayl","author":"Elmore","year":"2006"},{"key":"10.1016\/j.cbi.2018.09.019_bib64","first-page":"12549","article-title":"Effects of PPARgamma agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo","volume":"8","author":"Cao","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.cbi.2018.09.019_bib65","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1158\/1535-7163.MCT-10-0570","article-title":"Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition","volume":"9","author":"Reka","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.cbi.2018.09.019_bib66","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bjc.6603344","article-title":"Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells","volume":"95","author":"Cellai","year":"2006","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00411-016-0679-9","article-title":"Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells","volume":"56","author":"An","year":"2017","journal-title":"Radiat. Environ. Biophys."},{"key":"10.1016\/j.cbi.2018.09.019_bib68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2008.04.035","article-title":"Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo","volume":"371","author":"Kim","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2018.09.019_bib69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1500863","article-title":"PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas","volume":"150","author":"Bogazzi","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.cbi.2018.09.019_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.lungcan.2005.10.010","article-title":"PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression","volume":"51","author":"Lee","year":"2006","journal-title":"Lung Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib71","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1158\/1078-0432.CCR-08-1128","article-title":"Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin","volume":"14","author":"Girnun","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib72","first-page":"2113","article-title":"Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat","volume":"26","author":"Nunez","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2407-9-107","article-title":"Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats","volume":"9","author":"Tikoo","year":"2009","journal-title":"BMC Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib74","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2119\/2008-00021.Papageorgiou","article-title":"Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells","volume":"14","author":"Papageorgiou","year":"2008","journal-title":"Mol. Med."},{"key":"10.1016\/j.cbi.2018.09.019_bib75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cbi.2016.07.008","article-title":"Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-gamma-dependent mechanism","volume":"256","author":"Matsunaga","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2018.09.019_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjp.0705973","article-title":"GW9662, a potent antagonist of PPARc, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARc agonist rosiglitazone, independently of PPARc activation","volume":"143","author":"Seargent","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2018.09.019_bib77","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/ijc.21799","article-title":"Increased PTEN expression due to transcriptional activation of PPAR gamma by Lovastatin and Rosiglitazone","volume":"118","author":"Teresi","year":"2006","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040149","article-title":"Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells","volume":"7","author":"Cerbone","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2018.09.019_bib79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2005.09.010","article-title":"Differentiation and growth inhibition mediated via the RXR : PPAR gamma heterodimer in colon cancer","volume":"240","author":"Cesario","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2018.09.019_bib80","article-title":"Inhibition of oxidative stress-elicited AKT activation facilitates PPARgamma agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.cbi.2018.09.019_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-8-16","article-title":"Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression","volume":"8","author":"Klopper","year":"2009","journal-title":"Mol. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib82","first-page":"207","article-title":"The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells","volume":"27","author":"Freudlsperger","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib83","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5832824","article-title":"Combination treatment with PPARgamma ligand and its specific inhibitor GW9662 downregulates BIS and 14-3-3 gamma, inhibiting stem-like properties in glioblastoma cells","volume":"2017","author":"Im","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.cbi.2018.09.019_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3892\/ijo.2010.877","article-title":"Thiazolidinediones\/PPARgamma agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer","volume":"38","author":"Mansour","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib85","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/ijc.25189","article-title":"Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells","volume":"127","author":"Plissonnier","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib86","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cellsig.2013.12.004","article-title":"Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARgamma- and AMPKalpha-dependent signaling: role of AP-2alpha and Sp1","volume":"26","author":"Hahn","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cbi.2018.09.019_bib87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bbagen.2013.09.005","article-title":"PPARgamma-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone","volume":"1840","author":"Zhao","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2018.09.019_bib88","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/carcin\/bgp260","article-title":"Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model","volume":"30","author":"Lyon","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cbi.2018.09.019_bib89","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.30766","article-title":"Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years","volume":"141","author":"Snaebjornsson","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.30791","article-title":"Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE study","volume":"141","author":"Knight","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib91","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.18632\/oncotarget.13824","article-title":"Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2018.09.019_bib92","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-06-1947","article-title":"Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers","volume":"13","author":"Yee","year":"2007","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib93","first-page":"1129","article-title":"Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges","volume":"12","author":"Hoshida","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.cbi.2018.09.019_bib94","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ijc.30708","article-title":"Recent developments in nanomedicine for melanoma treatment","volume":"141","author":"Tang","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib95","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/ptr.3122","article-title":"Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells","volume":"24","author":"Freudlsperger","year":"2010","journal-title":"Phytother Res."},{"key":"10.1016\/j.cbi.2018.09.019_bib96","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.remn.2010.08.005","article-title":"Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake","volume":"30","author":"Elola","year":"2011","journal-title":"Rev. Espa\u00f1ola Med. Nucl."},{"key":"10.1016\/j.cbi.2018.09.019_bib97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00411-016-0679-9","article-title":"Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells","volume":"56","author":"An","year":"2017","journal-title":"Radiat. Environ. Biophys."},{"key":"10.1016\/j.cbi.2018.09.019_bib98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4161\/cbt.13.2.18872","article-title":"Inhibiting homologous recombination for cancer therapy","volume":"13","author":"Chernikova","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.cbi.2018.09.019_bib99","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.bbrc.2010.03.068","article-title":"Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells","volume":"394","author":"Chiu","year":"2010","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.cbi.2018.09.019_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2012.00322.x","article-title":"Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs","volume":"12","author":"Allstadt Frazier","year":"2014","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib101","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000140468","article-title":"A phase I study of bexarotene and rosiglitazone in patients with refractory cancers","volume":"54","author":"Read","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cbi.2018.09.019_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00280-012-1977-9","article-title":"Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"71","author":"Esteva","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2018.09.019_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e13042","article-title":"Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)","volume":"29","author":"Choueiri","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2018.09.019_bib104","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/sj.bjc.6601306","article-title":"A phase II trial with rosiglitazone in liposarcoma patients","volume":"89","author":"Debrock","year":"2003","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.cbi.2018.09.019_bib105","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.surg.2006.07.038","article-title":"A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer","volume":"140","author":"Kebebew","year":"2006","journal-title":"Surgery"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718308421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718308421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:51:33Z","timestamp":1757857893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279718308421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":105,"alternative-id":["S0009279718308421"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2018.09.019","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2018.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}